Hydroxamic acid - A novel molecule for anticancer therapy.

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Hydroxamic acid is a significant functional group in both cancer therapy and mutagenesis.
• Suberoylanilide Hydroxamic Acid (SAHA) is a notable derivative with potent anticancer properties.
• Histone acetylation/deacetylation by histone acetyltransferases and histone deacetylases regulates gene expression, with aberrant levels linked to cancers.

Purpose of the Study:

• To highlight the potential of hydroxamic acid derivatives as anticancer agents.
• To explore the synthesis of novel hydroxamic acid moieties with varied terminal groups.
• To emphasize the versatile activity of the hydroxamic acid moiety in therapeutic applications.

Main Methods:

• Synthesis of diverse hydroxamic acid derivatives with varied straight-chain oxazole, thiadiazole, and biphenyl moieties.
• Investigation of the role of histone acetylation in cancer etiology.
• Exploration of structure-activity relationships for novel anticancer candidates.

Main Results:

• Hydroxamic acid derivatives, including SAHA, demonstrate significant anticancer potential.
• Novel hydroxamic acid structures with diverse terminal groups have been synthesized.
• The hydroxamic acid moiety exhibits broad-ranging biological activities beyond receptor binding.

Conclusions:

• Hydroxamic acid derivatives are promising candidates for developing novel cancer treatments.
• Targeting histone acetylation pathways offers a viable strategy for cancer therapy.
• The versatility of the hydroxamic acid functional group supports its application in diverse therapeutic areas.